News

The Quebec-based company announced that during a recent end of phase II meeting, the FDA reviewed the safety and efficacy data from an extensive phase II program with

The groups have formed the European Partnership for Alternative Approaches to Animal Testing (EPAA), and committed to a five-year plan to reduce animal testing in product-safety checks. The

The filing is based on long-term data from two double-blind, placebo-controlled trials showing inhibition of structural damage and sustained improvement in functional status. Psoriatic arthritis is a chronic,

The deal includes an upfront cash payment of $5 million, but Cellera will only receive the $360 million if the program meets all developmental and commercial milestone events

Orphan drug designation provides companies with financial and regulatory benefits during the course of the drug development including tax credits related to clinical trial expenses and a possible

Analysis of blood samples taken six weeks post-vaccination with virosome-gp41 peptides have revealed the presence of anti-gp41 antibodies (IgG and IgA), confirming previous data from rabbit models. The

The first study was a phase IIa study of TA-CD conducted by Dr Margaret Haney, associate professor of Clinical Neuroscience at Columbia University. The study looked at the

The company will work with Dr Steven Rosenberg, chief, Surgery Branch, who has identified and characterized a number of melanoma tumor-associated antigens and has developed a lymphodepleting non-myeloablative

Shares in Evotec, which could receive milestone payments of more than E100 million as a result of the collaboration, rose as much as 15% after the news of